OUR MISSION

Bring relief to people living with rare and severe diseases

“It all started with a hug from a patient I met while working at a previous company,” said Patrick Reichenberger, CEO of AltiBio. He was at a patient meeting when the mother of an affected child asked to speak with him in private. Her eyes started to well up and she asked him if she could give him a hug. He said, “Of course!” She gently sobbed while giving him a squeeze and thanked him for making the therapy available for her daughter and their family. “It’s brought such relief,” she said. “It has changed our lives.”

This is just one example of the many powerful experiences which inspire the staff at AltiBio to seek to develop therapies that bring relief to people living with rare and severe diseases.

Learn More

COMPANY HISTORY

AltiBio, Inc. (AltiBio) was founded in 2017 by a team with successful experience developing and commercializing orphan therapeutics. AltiBio currently has several projects in development for an undisclosed rare disease: ATB226, ATB227, and ATB228.

Both the disease and the lead product candidate are closely tied with development projects that management has led to favorable clinical, regulatory, and commercial outcomes in their previous work together. The company has collected compelling data supporting its lead candidate and is ready to embark on the next stage of development. Series B funding is now being sought to carry the company through Phase 1.